NCT05163834View on ClinicalTrials.gov

Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

PHASE1CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

March 8, 2022

Study Completion Date

March 8, 2022

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

Efgartigimod

intravenous infusion of efgartigimod

OTHER

Placebo

intravenous infusion of placebo

BIOLOGICAL

PNEUMOVAX 23

PNEUMOVAX 23 vaccine

Trial Locations (1)

9728 NZ

Investigator site 1, Groningen

Sponsors

Lead Sponsor

All Listed Sponsors

lead

argenx

INDUSTRY